GLP-1 News

ITM targets US approval for radiopharmaceutical after Phase III readout

March 6, 2025
admin

The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.

Leave a Reply

Your email address will not be published. Required fields are marked *